Dr. Wai Liu received his PhD in Medical Oncology from St Bartholomew’s Hospital, University of London in 2001. During this time he developed models to assess the effect of combining chemotherapies with other treatment modalities as a way of enhancing activity.  Wai has worked in a cancer research environment for nearly thirty years. He has extensive experience progressing novel chemotherapy and immune-modulating drugs through pre-clinical investigations and developing patent portfolios. He has over fifteen years of experience working in a collaborative environment with multinational pharma including Novartis, Celgene and GW Pharma. He is a prominent scientist in the field of cannabinoid research, which is an area he has actively engaged for over twenty years.  His team was the first to demonstrate a benefit in combining cannabinoids and irradiation in models of brain cancer. Wai is interested in developing new combination strategies that utilise re-purposed drugs, including naltrexone, anti malarial drugs and immunomodulatory drugs like Thalidomide.  He has also investigated ways of enhancing anticancer activity by modifying the pathological associations between immune and tumour cells by using immune-targeting drugs. Wai is a key opinion leader on cannabis research and is regularly contacted by the media for his opinions on cannabinoids as a cancer treatment.